Flexion Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Flexion Therapeutics's estimated annual revenue is currently $4M per year.
- Flexion Therapeutics received $Undisclosed in venture funding in October 2017.
- Flexion Therapeutics's estimated revenue per employee is $77,500
- Flexion Therapeutics's total funding is $92M.
Employee Data
- Flexion Therapeutics has 51 Employees.
- Flexion Therapeutics grew their employee count by -19% last year.
Flexion Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP CMC Operations | Reveal Email/Phone |
2 | General Counsel & Corporate Secretary | Reveal Email/Phone |
3 | Chief Strategy Officer | Reveal Email/Phone |
4 | Director, Contracting & Pricing | Reveal Email/Phone |
5 | Director Quality Operations | Reveal Email/Phone |
6 | Associate Director, Events & Field Operations | Reveal Email/Phone |
7 | Chief Strategy Officer | Reveal Email/Phone |
8 | Director Strategic Accounts - Northeast | Reveal Email/Phone |
9 | Muscular Business Manager with Flexion Therapeutics | Reveal Email/Phone |
10 | Muskuloskeletal Business Manager | Reveal Email/Phone |
Flexion Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Flexion Therapeutics?
Flexion Therapeutics (NASDAQ: FLXN) is a biopharmaceutical company focused on the discovery, development & commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions. Flexion is based in Burlington, Massachusetts. View our terms of use: https://flexiontherapeutics.com/terms-of-use/
keywords:N/A
$92M
Total Funding
51
Number of Employees
$4M
Revenue (est)
-19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Flexion Therapeutics News
Horizon Therapeutics, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Abbott, Anika Therapeutics, Eli Lilly, Flexion Therapeutics.
Flexion Therapeutics: Florida-based Pacira BioSciences Inc. · Deciphera Pharmaceuticals: Deciphera Pharmaceuticals Inc. · Kaleido Biosciences:...
He most recently served as the CFO of Flexion Therapeutics. Prior to Flexion, Driscoll was the CFO of Novavax, Inc. He previously served as...
Flexion Therapeutics, a Woburn, MA-based company that discovers and develops innovative therapeutics for musculoskeletal disorders, has raised $20m in Series B financing. The round led by new investor Novo Ventures, with participation from existing investors 5AM Ventures, Pfizer Venture Investm ...
Flexion Therapeutics, aWoburn, MA-based developer of drug candidates through clinically meaningful proof of concept and beyond, has received an equity financing from Pfizer Venture Investments which allowed the company to close its $42m Series A financing round. The investment follow the comple ...
Other Companies in Burlington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 51 | 6% | N/A |
#2 | $15.1M | 51 | 4% | N/A |
#3 | $15.1M | 51 | 6% | N/A |
#4 | $4.6M | 51 | 9% | N/A |
#5 | $14.7M | 51 | 42% | N/A |
Flexion Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-10-19 | $33.0M | A | Versant Ventures | Article |
| 2010-02-01 | $9.0M | Undisclosed | Pfizer Venture Investments | Article |
| 2012-12-05 | $20.0M | B | Novo Ventures | Article |
| 2014-12-15 | $98.5M | Undisclosed | BMO Capital Markets Corp. | Article |
| 2015-08-05 | $30.0M | Undisclosed | MidCap Financial | Article |
| 2017-04-28 | $175.0M | Undisclosed | Article | |
| 2017-10-12 | $Undisclosed | Undisclosed | Wells Fargo Securities | Article |